Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 11/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14748357 | 0.85 | KMT2A (0.52) | IGF1RKDM4EMEN1MAPTKMT2A | |
| SCHEMBL1163804 | 0.84 | KDM4E (0.51) | IGF1RKDM4EMEN1MAPTKMT2A | |
| SCHEMBL22182518 | 0.82 | PTK2 (0.52) | IGF1RKDM4EMEN1MAPTKMT2A | |
| SCHEMBL1675598 | 0.80 | KDM4E (0.47) | IGF1RKDM4EMEN1MAPTKMT2A | |
| SCHEMBL21473640 | 0.79 | PTK2 (0.56) | IGF1RPTK2PLK1 | |
| SCHEMBL3538922 | 0.77 | HTR4 (0.47) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL3942580 | 0.77 | HTR4 (0.47) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL21610980 | 0.77 | HRH3 (0.59) | IGF1RKDM4EMEN1MAPTKMT2A | |
| SCHEMBL14924096 | 0.77 | KMT2A (0.51) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL3544454 | 0.76 | HTR7 (0.48) | KDM4EMEN1MAPTKMT2APTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | LRRK2, WEE1, WEE2 | IGF1R 1336/4885KDM4E 2114/4885MEN1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.